Abstract: Stereotactic body radiation therapy (SBRT) can achieve high-dose irradiation in the target areas of patients with ultra-central lung cancer (UCLC) while also protecting the surrounding organs at risk. SBRT is the gold standard of clinical treatment for patients with UCLC. Some clinical studies on SBRT for UCLC treatment have shown that it can obtain a better local control rate, median survival time, and overall survival rate than other known treatment methods. However, because UCLC tissues are close to organs at risk in the patient's mediastinum, SBRT treatment is often accompanied by toxicity and side effects. This article reviews the progress of research on SBRT for the treatment of patients with UCLC.